Iolab
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary receives a patent covering laser technology for fragmentation of cataracts prior to replacement with intraocular lenses. The probe incorporating the technology, which "is designed to be less invasive" than ultrasonic phacoemulsification, pulses laser energy onto a target in the device that converts the laser energy to soundwave energy. Iolab says the device can fit through 2.4 mm incisions as opposed to the 3 mm or greater required for phacoemulsification. In addition, "no heat is generated at the incision site," the firm says. Iolab has exclusive, world-wide development and marketing rights to the product, which was developed by patent recipient Jack Dodick, MD, Manhattan Eye, Ear and Throat Hospital. Six procedures were performed with the laser in 1991 under an investigational device exemption. More trials are slated for 1995
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.